A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer

Korábbi kezelés

• Subjects who underwent both tumor reduction surgery and gastrointestinal resection and reconstruction simultaneously;
• Previously allergic to chemotherapy drugs;
• Previously had a history of neurological or psychiatric disorders that would affect study informed consent or follow-up evaluation, such as severe depression or dementia;

Más betegség

• Subjects with severe abdominal infection (peritonitis);
• Subjects with portal vein thrombosis;
• Individuals with severe heart and lung, liver and kidney, blood system, or mental illnesses, as well as those who abuse drugs;

Laborértékek

• Patients with severe or uncontrolled medical conditions and infections (including atrial fibrillation, angina pectoris, heart failure, ejection fraction less than 50%, refractory hypertension, etc.);

Egyéb

• Subjects with gastrointestinal obstruction;
• Subjects who rely entirely on parenteral nutrition;
• Subjects with decompensated ascites;
• Subjects with extensive abdominal adhesion;
• Pregnant or lactating women;
• Patients who have participated in or are currently participating in other clinical trials within 3 months;
• Other situations where the researchers believe that the patient is not suitable to participate in this trial;

• Patients with peritoneal metastatic adenocarcinoma of colorectal origin, confirmed by histopathology, and without metastasis to other sites.
• No gender limitation, aged 18 to 75 years old;
• ECOG score ≤2;
• Subjects without other malignant diseases;
• Subjects without laparoscopic surgery contraindications;
• Expected survival period > 6 months;
• Able to comprehend and sign the informed consent form;
• The function of important organs should meet the following requirements; The absolute neutrophil count (ANC) is ≥1.5×10\^9/L; Platelets ≥ 100×10\^9/L; Hemoglobin ≥8.0g/dl (Note: It is acceptable to achieve hemoglobin ≥8.0g/dl through blood transfusion or other interventions); serum albumin ≥2.8g/dL; Bilirubin ≤1.5 times ULN, ALT and AST ≤1.5 times ULN; if there is liver metastasis, ALT and AST ≤5 times ULN; Creatinine clearance rate ≥50mL/min